Cancerfrom24/7 Wall St.1 day agoWave Life Sciences Slips as Obesity Data Fails to ConvinceWave Life Sciences shares plummet after disappointing Phase 1 trial data for obesity candidate WVE-007, prompting price target cuts from analysts.